Daré Bioscience (DARE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting of stockholders was adjourned due to lack of quorum and will reconvene on July 9, 2025, virtually.
Proxies and votes already submitted remain valid for the reconvened meeting unless revoked.
Record date for voting eligibility remains April 17, 2025.
No changes have been made to the proposals to be voted on at the reconvened meeting.
Voting matters and shareholder proposals
Stockholders are encouraged to vote online or by phone by July 8, 2025, to ensure their votes are counted.
Proposals to be voted on remain unchanged from those previously distributed.
Shareholder rights and capital structure
Only stockholders of record as of April 17, 2025, or their legal proxy holders, may attend and vote at the reconvened meeting.
Voting instructions and deadlines are provided for both direct and beneficial holders.
Latest events from Daré Bioscience
- Q2 net income hit $12.9M on royalty sale, but liquidity and future losses remain concerns.DARE
Q2 20241 Feb 2026 - Q3 net loss narrowed, major funding secured, but liquidity risks and capital needs persist.DARE
Q3 202413 Jan 2026 - Sildenafil cream to launch via 503B in Q4 2025; pipeline advances amid funding and enrollment shifts.DARE
Q4 202426 Dec 2025 - Shareholders will vote on director elections, auditor ratification, executive pay, and a stock plan amendment.DARE
Proxy Filing2 Dec 2025 - Shareholders to vote on directors, auditor, executive pay, and stock plan amendment.DARE
Proxy Filing2 Dec 2025 - Up to 2.75M shares registered for resale to fund R&D, with potential for significant dilution.DARE
Registration Filing29 Nov 2025 - Net loss narrows, but liquidity risks persist as revenue from new products is targeted for Q4 2025.DARE
Q1 202526 Nov 2025 - Sildenafil cream and Ovaprene advance, with revenue and key milestones expected in 2024.DARE
Jones Healthcare and Technology Innovation Conference 202525 Nov 2025 - Q2 2025 saw a $4.0M net loss, improved liquidity, and DARE to PLAY set for Q4 launch.DARE
Q2 202523 Nov 2025